Medical School · Year 2 · Msk Dermatology · includes a quiz and discussion video

Lecture 04: Connective Tissue Diseases

Unit 2.10: Musculoskeletal and Dermatology

Learning Objectives

By the end of this lecture, students will be able to:

1. Describe the clinical features and diagnosis of systemic lupus erythematosus
2. Explain the clinical manifestations and management of systemic sclerosis
3. Describe Sjogren syndrome and its complications
4. Explain the inflammatory myopathies (dermatomyositis, polymyositis)
5. Describe mixed connective tissue disease
6. Explain the vasculitides associated with connective tissue diseases

Lecture Outline

I. Systemic Lupus Erythematosus Overview

Systemic lupus erythematosus (SLE) represents the prototypical systemic autoimmune disease, characterized by the production of autoantibodies against nuclear and cytoplasmic antigens and the deposition of immune complexes that cause tissue damage in virtually any organ system. The disease follows a relapsing-remitting course with periods of active inflammation alternating with quiescent phases, though some patients experience chronic persistent activity. The hallmark of SLE is the production of autoantibodies, particularly antinuclear antibodies (ANA), which are present in essentially all patients and serve as a sensitive screening marker. The pathogenesis involves a complex interplay of genetic predisposition, environmental triggers, and immune dysregulation resulting in loss of tolerance to self-antigens.

The epidemiology of SLE demonstrates striking demographic patterns that inform understanding of disease pathogenesis. Prevalence ranges from 20 to 150 cases per 100,000 population, varying by geographic region and ethnicity. Women are affected approximately nine times more frequently than men, with this female predominance suggesting a significant role for sex hormones, particularly estrogen, in disease susceptibility and expression. Peak age of onset occurs between 15 and 44 years, during the reproductive years. Certain ethnic groups, including African Americans, Hispanics, and Asians, demonstrate higher prevalence and often more severe disease than Caucasian populations, reflecting contributions from both genetic and socioeconomic factors.

Genetic and environmental risk factors interact to produce disease in susceptible individuals. Genetic associations include HLA-DR2 and HLA-DR3, as well as inherited deficiencies of early complement components (C1q, C2, C4), which impair clearance of apoptotic cells and immune complexes. Multiple non-HLA genetic variants contribute smaller effects through genome-wide association studies. Hormonal factors are implicated by the female predominance, disease flares during pregnancy or with oral contraceptive use, and effects of estrogen on B cell activation and survival. Environmental triggers include ultraviolet light exposure, which can induce disease flares and potentially initial onset. Certain medications can cause drug-induced lupus, typically featuring positive anti-histone antibodies; common culprits include hydralazine, procainamide, and isoniazid, with disease generally remitting upon drug discontinuation.

The pathogenesis of SLE centers on defective clearance of apoptotic cells, leading to exposure of nuclear antigens to the immune system and subsequent breakdown of tolerance. Impaired clearance by macrophages and complement allows nuclear antigens from dying cells to accumulate and be processed by dendritic cells. B cell hyperactivity results in production of autoantibodies that form immune complexes with their target antigens. These immune complexes deposit in tissues including kidney glomeruli, skin, and blood vessel walls, where they activate complement and recruit inflammatory cells, causing tissue damage. Type I interferon signatures are prominent in SLE, with interferon-alpha produced in response to nucleic acid-containing immune complexes contributing to disease pathogenesis and serving as a therapeutic target.

<image>Panel A: Diagram illustrating SLE pathogenesis showing impaired apoptotic cell clearance, nuclear antigen exposure, dendritic cell activation, B cell autoantibody production, immune complex formation, tissue deposition, and complement-mediated inflammation. Panel B: Epidemiology infographic showing 9:1 female to male ratio, peak onset ages 15-44, and higher prevalence in African American, Hispanic, and Asian populations compared to Caucasians. Panel C: Genetic susceptibility diagram showing HLA associations (DR2, DR3), complement deficiencies (C1q, C2, C4), and multiple non-HLA risk alleles with their relative contributions to disease risk. Panel D: Environmental trigger illustration showing ultraviolet light inducing keratinocyte apoptosis and translocation of nuclear antigens to cell surface, drug-induced lupus mechanisms, and potential infectious triggers.</image>

II. Clinical Features of Systemic Lupus Erythematosus

Constitutional symptoms affect more than 90% of SLE patients and may dominate the clinical picture, particularly during disease flares. Fatigue is nearly universal and often disproportionate to objective disease activity, significantly impacting quality of life and functional capacity. Fever occurs in 50-80% of patients during active disease, though infection must always be excluded as SLE patients are susceptible to infections due to both disease and immunosuppressive therapy. Weight loss accompanies active disease and contributes to the debilitation experienced by many patients. Lymphadenopathy is found in 30-50% of patients and may be generalized or localized, typically featuring soft, nontender nodes that must be distinguished from infection or malignancy.

Mucocutaneous manifestations represent some of the most recognizable features of SLE and significantly impact patient self-image and quality of life. The malar or butterfly rash, present in approximately half of patients, consists of erythema over the cheeks and nasal bridge characteristically sparing the nasolabial folds, distinguishing it from conditions like rosacea. Discoid lupus lesions are chronic, scarring plaques with follicular plugging, scale, and central atrophy that may progress to permanent hypopigmentation, particularly affecting darker-skinned individuals. Photosensitivity manifests as exaggerated sunburn or rash following ultraviolet exposure and may trigger systemic flares. Oral ulcers, typically painless and occurring on the hard palate or other mucosal surfaces, are included in classification criteria. Alopecia may be diffuse (lupus hair) or patchy (discoid) and can be distressing. Subacute cutaneous lupus erythematosus presents with annular or papulosquamous lesions in photodistributed areas.

Musculoskeletal involvement is extremely common, affecting more than 90% of patients, though the pattern differs from rheumatoid arthritis. Arthralgias and arthritis are typically symmetric and polyarticular, resembling rheumatoid arthritis in distribution but characteristically non-erosive. Morning stiffness and joint swelling occur but usually do not progress to joint destruction. Jaccoud arthropathy, occurring in approximately 5% of patients, produces reducible deformities from ligamentous laxity rather than bony erosion, distinguishing it from rheumatoid deformity. Avascular necrosis, particularly affecting the hip and knee, occurs more frequently in SLE patients, related both to the disease itself and to corticosteroid therapy. Myalgias are common, though true inflammatory myositis is less frequent.

Lupus nephritis represents one of the most serious manifestations, occurring in approximately 50% of patients and significantly impacting prognosis. The World Health Organization and International Society of Nephrology/Renal Pathology Society classification system categorizes lupus nephritis into six classes based on renal biopsy findings. Class I (minimal mesangial) and Class II (mesangial proliferative) represent milder disease with better prognosis. Class III (focal proliferative) involves less than 50% of glomeruli, while Class IV (diffuse proliferative) involves 50% or more and carries the worst prognosis among proliferative forms. Class V (membranous) may occur alone or superimposed on proliferative disease. Class VI (advanced sclerosing) represents end-stage disease with more than 90% glomerulosclerosis. Clinical manifestations include proteinuria, hematuria, cellular casts, hypertension, and renal insufficiency, with early detection through routine urinalysis essential for preserving renal function.

<image>Panel A: Clinical photographs of mucocutaneous manifestations including malar rash (butterfly distribution sparing nasolabial folds), discoid lesions (scarring plaques with central atrophy), oral ulcers on hard palate, and diffuse alopecia. Panel B: Diagram comparing lupus arthritis (non-erosive, reducible Jaccoud deformity) with rheumatoid arthritis (erosive, fixed deformity), showing radiographic differences. Panel C: Lupus nephritis classification with kidney biopsy illustrations showing Class I-VI histological patterns, clinical manifestations (proteinuria, hematuria, hypertension), and prognosis for each class. Panel D: Systems involvement diagram showing frequencies of constitutional (greater than 90%), mucocutaneous (80%), musculoskeletal (greater than 90%), renal (50%), neuropsychiatric (30-50%), and hematologic (variable) manifestations.</image>

III. Diagnosis and Monitoring of SLE

The 2019 European League Against Rheumatism/American College of Rheumatology (EULAR/ACR) classification criteria provide a systematic approach to SLE diagnosis using an entry criterion followed by additive scoring across multiple domains. The entry criterion requires a positive ANA at a titer of 1:80 or greater at any time, without which the criteria cannot be applied. Patients meeting the entry criterion are then scored across clinical domains (constitutional, hematologic, neuropsychiatric, mucocutaneous, serosal, musculoskeletal, renal) and immunologic criteria, with classification as SLE requiring a total score of 10 or more points. Each criterion is assigned different point values reflecting its specificity for SLE, and criteria should not be counted if better explained by another diagnosis.

Autoantibody testing provides crucial diagnostic and prognostic information in SLE evaluation. Antinuclear antibodies (ANA) are present in approximately 95% of SLE patients and serve as a sensitive screening test, though they lack specificity and occur in other autoimmune diseases, infections, malignancies, and even healthy individuals. Anti-double-stranded DNA (anti-dsDNA) antibodies are highly specific for SLE and correlate with disease activity, particularly nephritis, with rising titers often heralding flares. Anti-Smith (anti-Sm) antibodies are the most specific serological marker for SLE (essentially pathognomonic) but are present in only 25-30% of patients. Anti-histone antibodies characterize drug-induced lupus. Anti-Ro (SSA) and anti-La (SSB) antibodies are associated with subacute cutaneous lupus, neonatal lupus with congenital heart block, and Sjogren syndrome overlap. Anti-RNP antibodies suggest mixed connective tissue disease overlap.

Laboratory findings beyond autoantibodies reflect disease activity and organ involvement. Hematologic abnormalities are common: anemia may be from chronic disease, hemolytic (positive Coombs test), or iron deficiency; leukopenia and lymphopenia reflect disease activity; thrombocytopenia may be immune-mediated. Complement levels (C3, C4, and total hemolytic complement) are typically decreased during active disease due to consumption by immune complexes and serve as activity markers. The erythrocyte sedimentation rate (ESR) is usually elevated during active disease, but interestingly, C-reactive protein (CRP) is often normal or only minimally elevated in SLE unless serositis or infection is present, a distinctive feature that may help distinguish lupus flare from infection. Urinalysis demonstrating proteinuria, hematuria, or cellular casts indicates renal involvement.

Disease activity monitoring employs validated composite indices and laboratory markers to guide treatment decisions. The Systemic Lupus Erythematosus Disease Activity Index (SLEDAI) incorporates clinical features and laboratory values to generate a score reflecting current disease activity. Serial measurement of anti-dsDNA antibodies and complement levels helps track disease trajectory, with rising anti-dsDNA and falling complement often predicting flares. Renal monitoring includes regular urinalysis for proteinuria and sediment, quantitative protein excretion, and serum creatinine. Renal biopsy is indicated when nephritis is suspected to guide treatment intensity and assess prognosis. The treat-to-target approach, analogous to rheumatoid arthritis management, aims for remission or low disease activity with organ-protective immunosuppression.

<image>Panel A: 2019 EULAR/ACR classification criteria flowchart showing entry criterion (ANA 1:80 or greater), clinical domains with point values (hematologic, neuropsychiatric, mucocutaneous, serosal, musculoskeletal, renal), immunologic criteria (anti-dsDNA, anti-Sm, antiphospholipid, complement, Coombs), and classification threshold of 10 or more points. Panel B: Autoantibody patterns diagram showing ANA as screening test with reflex to specific antibodies, sensitivity and specificity of anti-dsDNA, anti-Sm, and anti-histone, and clinical associations for each antibody. Panel C: Laboratory monitoring panel showing expected values during active disease (low C3/C4, elevated anti-dsDNA, high ESR with often normal CRP, cytopenias) versus remission. Panel D: SLEDAI scoring components illustration with clinical manifestations and their point contributions, demonstrating how composite scores guide treatment intensity.</image>

IV. Treatment of Systemic Lupus Erythematosus

General management measures address modifiable risk factors and provide foundation for pharmacological therapy. Sun protection is essential for all SLE patients given the role of ultraviolet light in triggering flares; recommendations include sun-protective clothing, broad-spectrum sunscreen with SPF 30 or higher applied daily, and avoidance of peak sun exposure hours. Smoking cessation is important both for cardiovascular risk reduction (particularly significant given accelerated atherosclerosis in SLE) and because smoking may reduce hydroxychloroquine efficacy. Vaccinations should be administered before initiating immunosuppressive therapy when possible, with annual influenza and pneumococcal vaccines recommended; live vaccines are generally contraindicated during significant immunosuppression. Cardiovascular risk factor management addresses the accelerated atherosclerosis through lipid management, blood pressure control, and disease activity control.

Hydroxychloroquine serves as the foundation of SLE therapy and is recommended for essentially all patients without contraindication. This antimalarial medication reduces flare frequency, improves survival, provides cardiovascular protection, and may reduce thrombosis risk in antiphospholipid antibody-positive patients. The mechanism involves accumulation in lysosomes, altering antigen processing, and reducing Toll-like receptor activation. Long-term use requires ophthalmologic monitoring for retinal toxicity, with annual examinations recommended after 5 years of use (or earlier with risk factors). Hydroxychloroquine can be continued during pregnancy and is associated with reduced neonatal lupus risk in anti-Ro positive mothers. Low-dose glucocorticoids may supplement hydroxychloroquine for mild disease, with nonsteroidal anti-inflammatory drugs providing symptomatic relief for arthralgias.

Moderate to severe disease requires addition of glucocorticoids and often immunosuppressive agents based on organ involvement and severity. Glucocorticoids provide rapid disease control but carry substantial long-term toxicity; the goal is to achieve disease control and then taper to the lowest effective dose, preferably eliminating or reducing to prednisone 5 mg or less daily. Immunosuppressive agents allow glucocorticoid sparing while maintaining disease control. Azathioprine serves as a maintenance agent, particularly for nephritis or as steroid-sparing therapy. Mycophenolate mofetil has become a preferred agent for both induction and maintenance of lupus nephritis, with efficacy comparable to cyclophosphamide for induction with a more favorable safety profile. Cyclophosphamide remains important for severe organ-threatening disease, particularly severe nephritis and central nervous system involvement.

Lupus nephritis management follows a two-phase approach of induction to achieve remission followed by maintenance to prevent relapse. Induction therapy for proliferative nephritis (Class III or IV) typically employs either mycophenolate mofetil or cyclophosphamide combined with glucocorticoids, with mycophenolate often preferred given comparable efficacy and better tolerability. Maintenance therapy with mycophenolate or azathioprine continues for extended periods, often years, to prevent relapse. Belimumab, a monoclonal antibody targeting B lymphocyte stimulator (BLyS), is approved as add-on therapy for active disease despite standard treatment and has demonstrated renal benefit. Rituximab, depleting CD20-positive B cells, is used for refractory disease despite lack of consistent trial success. Voclosporin, a novel calcineurin inhibitor, has recently been approved for lupus nephritis in combination with mycophenolate.

<image>Panel A: Treatment algorithm stratified by disease severity showing mild disease (hydroxychloroquine plus or minus low-dose glucocorticoids), moderate disease (addition of immunosuppressives), and severe/organ-threatening disease (high-dose glucocorticoids, cyclophosphamide or mycophenolate), with transitions between levels. Panel B: Hydroxychloroquine central role diagram showing multiple benefits (flare reduction, survival improvement, cardiovascular protection, thrombosis reduction) and monitoring requirements (ophthalmologic examination schedule). Panel C: Lupus nephritis treatment phases showing induction (mycophenolate or cyclophosphamide with glucocorticoids, 3-6 months) and maintenance (mycophenolate or azathioprine, years), with response assessment milestones. Panel D: Novel therapies diagram showing belimumab mechanism (BLyS inhibition, B cell survival reduction), rituximab (B cell depletion), and voclosporin (calcineurin inhibition) with their roles in refractory or active disease.</image>

V. Systemic Sclerosis Overview and Classification

Systemic sclerosis, also known as scleroderma, is a connective tissue disease characterized by fibrosis of the skin and internal organs, vasculopathy affecting small blood vessels, and autoimmune features including production of specific autoantibodies. The disease results from a complex pathogenic process involving immune activation, vascular injury, and fibroblast activation leading to excessive collagen deposition. Classification into limited cutaneous and diffuse cutaneous subtypes based on the extent of skin involvement carries significant prognostic implications for organ involvement patterns and survival. The limited form was previously known by the CREST acronym, highlighting its characteristic manifestations.

Limited cutaneous systemic sclerosis (lcSSc) affects skin distal to the elbows and knees, with facial involvement but sparing the trunk. The CREST syndrome features encompass the major manifestations: Calcinosis (subcutaneous calcium deposits), Raynaud phenomenon (virtually universal), Esophageal dysmotility (heartburn, dysphagia), Sclerodactyly (skin thickening of fingers), and Telangiectasia (dilated capillaries on face and hands). Limited disease generally follows an indolent course with skin involvement developing gradually over years. However, patients remain at risk for serious complications including pulmonary arterial hypertension (PAH), which represents a major cause of mortality in limited disease. Interstitial lung disease may also occur but is typically less severe than in diffuse disease.

Diffuse cutaneous systemic sclerosis (dcSSc) involves widespread skin thickening including the trunk and proximal extremities, typically developing more rapidly than limited disease. Skin involvement often progresses over months to years, eventually stabilizing and sometimes partially regressing. Internal organ involvement tends to be more extensive and severe than in limited disease, with interstitial lung disease being particularly common and representing a major cause of morbidity and mortality. Renal crisis, now less common with prophylactic ACE inhibitor use awareness, occurs predominantly in diffuse disease. Cardiac involvement with myocardial fibrosis and conduction abnormalities is more frequent. The overall prognosis for diffuse disease is generally poorer than for limited disease, though survival has improved with better recognition and management of complications.

Autoantibodies in systemic sclerosis demonstrate strong associations with clinical subtype and specific organ manifestations, providing valuable prognostic information. Anti-centromere antibodies (ACA) are found in approximately 60% of limited cutaneous disease and associate with lower risk of interstitial lung disease but increased risk of pulmonary arterial hypertension; they rarely occur in diffuse disease. Anti-topoisomerase I antibodies (anti-Scl-70) characterize diffuse cutaneous disease and strongly predict interstitial lung disease, occurring in approximately 30% of diffuse cases. Anti-RNA polymerase III antibodies associate with diffuse cutaneous disease, rapid skin progression, and significantly increased risk of scleroderma renal crisis; they also correlate with increased malignancy risk prompting cancer screening. These antibody associations guide both monitoring strategies and prognostic counseling.

<image>Panel A: Comparison of limited versus diffuse cutaneous systemic sclerosis showing body diagrams with areas of skin involvement highlighted, timeline of skin progression, and associated organ manifestations for each subtype. Panel B: CREST syndrome components illustrated showing calcinosis (calcium deposits in fingers on radiograph), Raynaud phenomenon (digital color changes), esophageal dysmotility (barium swallow with dilated esophagus), sclerodactyly (tapered digits with tight skin), and telangiectasia (facial and mucosal). Panel C: Autoantibody associations diagram showing anti-centromere (limited disease, PAH risk), anti-Scl-70 (diffuse disease, ILD risk), and anti-RNA polymerase III (diffuse disease, renal crisis and malignancy risk) with percentages and clinical implications. Panel D: Pathogenesis illustration showing the triad of immune activation (T cells, B cells, autoantibodies), vasculopathy (endothelial injury, intimal proliferation), and fibrosis (fibroblast activation, excessive collagen deposition) and their interconnections.</image>

VI. Systemic Sclerosis Complications and Management

Pulmonary complications represent the leading cause of death in systemic sclerosis, with both interstitial lung disease (ILD) and pulmonary arterial hypertension (PAH) contributing to mortality. Interstitial lung disease occurs in approximately 80% of patients with diffuse disease and 30% with limited disease, though clinically significant disease is less common. Screening with pulmonary function tests (forced vital capacity, diffusing capacity for carbon monoxide) and high-resolution CT identifies patients requiring treatment. Nonspecific interstitial pneumonia (NSIP) is the most common histologic pattern. Treatment with immunosuppression (mycophenolate mofetil preferred based on Scleroderma Lung Study II results) and antifibrotic agents (nintedanib, approved for SSc-ILD) can slow progression. Pulmonary arterial hypertension, screened for with echocardiography and confirmed by right heart catheterization, requires pulmonary vasodilator therapy.

Scleroderma renal crisis represents a life-threatening complication occurring predominantly in early diffuse disease, characterized by acute onset of severe hypertension, rapidly progressive acute kidney injury, and microangiopathic hemolytic anemia. Risk factors include diffuse cutaneous disease within the first four years of diagnosis, rapid skin progression, anti-RNA polymerase III antibodies, and notably high-dose corticosteroid use (greater than 15 mg prednisone daily). Pathologically, renal crisis reflects thrombotic microangiopathy affecting renal arterioles. Treatment with ACE inhibitors is critical, even in the presence of renal insufficiency, as ACE inhibitors improve outcomes; they should be continued unless hyperkalemia becomes unmanageable. Before ACE inhibitor availability, renal crisis was frequently fatal; current 1-year survival approaches 80% with prompt treatment, though many patients require temporary or permanent dialysis.

Gastrointestinal involvement affects approximately 90% of systemic sclerosis patients and significantly impacts quality of life. Esophageal dysmotility with lower esophageal sphincter incompetence causes gastroesophageal reflux disease (GERD), which predisposes to Barrett esophagus and requires aggressive acid suppression with proton pump inhibitors. Esophageal strictures may develop requiring dilation. Small intestinal dysmotility can lead to small intestinal bacterial overgrowth (SIBO) causing malabsorption, bloating, and diarrhea; treatment involves rotating antibiotics. Large intestinal involvement causes constipation and wide-mouth diverticula unique to scleroderma. Gastric antral vascular ectasia (watermelon stomach) can cause chronic gastrointestinal bleeding and iron deficiency anemia.

Management of systemic sclerosis requires an organ-based approach targeting specific manifestations, as no therapy has proven effective for reversing skin fibrosis or altering overall disease course. Raynaud phenomenon management involves cold avoidance, calcium channel blockers (nifedipine, amlodipine), and phosphodiesterase-5 inhibitors (sildenafil, tadalafil) for refractory cases. Digital ulcers, painful and prone to infection, are treated with vasodilators; iloprost (intravenous prostacyclin) and bosentan (endothelin receptor antagonist) reduce new ulcer formation. Interstitial lung disease is treated with mycophenolate mofetil and nintedanib. Pulmonary arterial hypertension requires pulmonary vasodilators including phosphodiesterase-5 inhibitors, endothelin receptor antagonists, and prostacyclin analogs, often in combination. Skin involvement lacks proven therapy; immunosuppression may be considered in early rapidly progressive disease.

<image>Panel A: Pulmonary complications management flowchart showing screening approach (PFTs, echocardiography), decision points for HRCT and right heart catheterization, and treatment pathways for ILD (mycophenolate, nintedanib) versus PAH (pulmonary vasodilators). Panel B: Scleroderma renal crisis recognition and management diagram showing risk factors (diffuse disease, anti-RNA pol III, high-dose steroids), clinical presentation (hypertensive crisis, AKI, MAHA), and treatment (ACE inhibitor critical, regardless of renal function). Panel C: Gastrointestinal manifestations by region showing esophageal dysmotility (GERD, strictures), small intestinal dysmotility (SIBO, malabsorption), and large intestinal involvement (constipation, diverticula), with treatment approaches. Panel D: Raynaud phenomenon and digital ulcer management ladder showing lifestyle modifications, calcium channel blockers, PDE-5 inhibitors, and prostacyclin analogs with expected benefits at each level.</image>

VII. Sjogren Syndrome

Sjogren syndrome is a chronic autoimmune exocrinopathy characterized by lymphocytic infiltration of salivary and lacrimal glands, resulting in impaired secretion and the cardinal sicca symptoms of dry eyes (keratoconjunctivitis sicca) and dry mouth (xerostomia). Primary Sjogren syndrome occurs in isolation, while secondary Sjogren syndrome develops in association with other connective tissue diseases, most commonly rheumatoid arthritis and systemic lupus erythematosus. The disease predominantly affects women, with a female to male ratio of approximately 9:1, and typically presents between ages 40 and 60. Beyond glandular involvement, Sjogren syndrome is a systemic disease with extraglandular manifestations affecting lungs, kidneys, nervous system, and other organs.

Clinical features extend beyond sicca symptoms, though these remain the defining manifestations. Dry eyes cause foreign body sensation, burning, photosensitivity, and increased susceptibility to corneal damage and infection. Dry mouth leads to difficulty swallowing dry foods, altered taste, increased dental caries, and oral candidiasis. Parotid gland enlargement, usually bilateral, occurs in one-third of patients. Fatigue is prominent and significantly impacts quality of life. Arthralgias affect approximately half of patients, though erosive arthritis is uncommon. Extraglandular manifestations include interstitial lung disease (most commonly nonspecific interstitial pneumonia pattern), renal tubular acidosis (type I, distal), interstitial nephritis, peripheral neuropathy (sensory more common than motor), and cutaneous vasculitis.

Diagnosis relies on a combination of clinical features, serological findings, and objective measures of glandular function. The Schirmer test measures tear production by placing filter paper strips in the lower eyelid; less than 5 mm of wetting in 5 minutes indicates reduced lacrimation. Rose bengal or lissamine green staining identifies ocular surface damage on slit-lamp examination. Salivary gland biopsy of minor labial glands demonstrating focal lymphocytic sialadenitis with a focus score of 1 or more (foci of 50 or more lymphocytes per 4 mm2) is highly specific. Anti-Ro (SSA) antibodies are present in 60-70% of patients, while anti-La (SSB) antibodies occur in 30-40% and are more specific. Rheumatoid factor is positive in approximately 50-75% of patients. ANA positivity is found in approximately 80%.

The most serious complication of Sjogren syndrome is the markedly increased risk of B-cell non-Hodgkin lymphoma, with a lifetime risk of 5-10%, representing a 15-20 fold increase over the general population. The most common types are marginal zone lymphoma (including mucosa-associated lymphoid tissue or MALT lymphoma) and diffuse large B-cell lymphoma. Risk factors for lymphoma development include persistent parotid gland enlargement, lymphadenopathy, palpable purpura from cutaneous vasculitis, low complement levels, cryoglobulinemia, and high disease activity. Surveillance for lymphoma development is important in high-risk patients. Treatment of Sjogren syndrome is primarily symptomatic, with artificial tears and saliva substitutes for sicca symptoms, pilocarpine or cevimeline (muscarinic agonists) to stimulate secretion, and immunosuppression reserved for serious extraglandular manifestations.

<image>Panel A: Salivary gland biopsy histology showing normal gland tissue compared to Sjogren syndrome with focal lymphocytic sialadenitis, demonstrating lymphocyte foci and acinar destruction. Panel B: Clinical manifestations diagram showing glandular features (dry eyes with corneal damage, dry mouth with dental caries, parotid enlargement) and extraglandular manifestations (ILD, RTA, peripheral neuropathy, vasculitis) with frequencies. Panel C: Diagnostic approach flowchart showing clinical suspicion (sicca symptoms, fatigue, arthralgias), objective testing (Schirmer test, ocular staining, salivary gland biopsy), serological testing (anti-Ro, anti-La, RF, ANA), and classification criteria application. Panel D: Lymphoma risk stratification showing risk factors (persistent parotid enlargement, low complement, cryoglobulinemia, cutaneous vasculitis) and recommended surveillance approach.</image>

VIII. Inflammatory Myopathies

The inflammatory myopathies are a heterogeneous group of autoimmune conditions characterized by muscle inflammation and weakness, with dermatomyositis, polymyositis, immune-mediated necrotizing myopathy, inclusion body myositis, and antisynthetase syndrome representing distinct clinicopathological entities. Classification has evolved with recognition that these conditions have different pathogenic mechanisms, clinical associations, and responses to treatment. The presence of characteristic skin findings defines dermatomyositis, while polymyositis is increasingly recognized as a diagnosis of exclusion after ruling out other myopathies. Myositis-specific autoantibodies have emerged as important tools for classification and prognostication.

Dermatomyositis features distinctive cutaneous manifestations that may precede, accompany, or follow muscle disease. The heliotrope rash, a purple or lilac discoloration of the eyelids often with edema, is pathognomonic. Gottron papules are scaly, erythematous to violaceous papules over the dorsal aspects of finger joints (MCPs, PIPs, DIPs), elbows, and knees. The V-sign describes erythema over the anterior neck and upper chest, while the shawl sign affects the upper back and posterior shoulders. Mechanic's hands, characterized by roughened, cracked skin on the lateral and palmar aspects of the fingers resembling manual laborer's hands, occur particularly in antisynthetase syndrome. Calcinosis, more common in juvenile dermatomyositis, involves calcium deposition in skin and muscle. Nail fold capillary abnormalities with dilated loops and dropout are characteristic.

Muscle involvement produces symmetric, proximal weakness affecting shoulder and hip girdle muscles, manifesting as difficulty climbing stairs, rising from chairs, and reaching overhead. Weakness develops subacutely over weeks to months, distinguishing inflammatory myopathy from the years-long progression of most muscular dystrophies. Neck flexor weakness (difficulty lifting the head from pillow) is common and relatively specific. Dysphagia from pharyngeal muscle involvement occurs in up to one-third of patients. Respiratory muscle weakness in severe cases can cause ventilatory failure. Creatine kinase (CK) is typically markedly elevated, often 10-100 times normal levels, reflecting muscle fiber damage. Electromyography shows myopathic changes with insertional irritability, and MRI demonstrates muscle edema in active disease. Muscle biopsy reveals characteristic histopathological patterns.

Myositis-specific autoantibodies correlate with distinct clinical phenotypes and guide prognosis. Anti-Mi-2 antibodies are associated with classic dermatomyositis with prominent skin findings and generally good prognosis, responding well to treatment. Anti-Jo-1 and other antisynthetase antibodies (anti-PL-7, anti-PL-12, anti-EJ, anti-OJ) define the antisynthetase syndrome, featuring myositis, interstitial lung disease, non-erosive arthritis, mechanic's hands, fever, and Raynaud phenomenon; ILD drives morbidity and mortality. Anti-MDA5 (melanoma differentiation-associated gene 5) antibodies associate with clinically amyopathic dermatomyositis and rapidly progressive, often fatal, interstitial lung disease. Anti-TIF1-gamma antibodies strongly associate with malignancy in adult dermatomyositis, prompting thorough cancer screening. Anti-SRP and anti-HMGCR antibodies characterize immune-mediated necrotizing myopathy, with anti-HMGCR occurring in statin-associated myopathy.

<image>Panel A: Clinical photographs of dermatomyositis cutaneous features including heliotrope rash (periorbital violaceous discoloration with edema), Gottron papules (erythematous papules over MCP, PIP joints), V-sign (anterior chest erythema), shawl sign (upper back involvement), and mechanic's hands (cracked, rough skin on fingers). Panel B: Muscle biopsy comparison showing dermatomyositis (perifascicular atrophy, perivascular inflammation), polymyositis (endomysial CD8+ T cell infiltration), and immune-mediated necrotizing myopathy (necrotic and regenerating fibers with minimal inflammation). Panel C: Myositis-specific antibody associations diagram showing anti-Mi-2 (classic DM, good prognosis), anti-Jo-1 (antisynthetase syndrome, ILD), anti-MDA5 (rapidly progressive ILD), anti-TIF1-gamma (malignancy association), and anti-HMGCR (statin-associated necrotizing myopathy) with clinical features for each. Panel D: Clinical assessment of proximal weakness showing testing of shoulder abduction (deltoid), hip flexion (iliopsoas), and neck flexion, with expected findings in inflammatory myopathy.</image>

IX. Inflammatory Myopathy Treatment and Cancer Association

Treatment of dermatomyositis and polymyositis employs a similar approach, beginning with glucocorticoids and adding steroid-sparing immunosuppression for refractory disease or to facilitate glucocorticoid taper. Induction therapy typically involves high-dose glucocorticoids, often prednisone 1 mg/kg/day (or equivalent), with gradual taper guided by clinical response and CK normalization. Muscle strength recovery lags behind biochemical improvement and may take months. Steroid-sparing agents are frequently added early given the prolonged treatment course and significant glucocorticoid toxicity. Methotrexate and azathioprine represent first-line steroid-sparing options, with selection influenced by tolerability, comorbidities, and presence of lung disease (methotrexate relatively contraindicated in ILD). Mycophenolate mofetil serves as an alternative.

Refractory disease or specific manifestations may require additional interventions. Intravenous immunoglobulin (IVIG) is effective for dermatomyositis, with randomized trial support, and is often used for refractory skin disease, dysphagia, or as steroid-sparing therapy. Rituximab, depleting B cells, has shown benefit in refractory myositis, particularly in antisynthetase syndrome and anti-SRP positive disease. Calcineurin inhibitors (tacrolimus, cyclosporine) may benefit certain patients. Physical therapy to maintain range of motion and rebuild strength is an essential component of management once inflammation is controlled; early aggressive exercise is avoided to prevent further muscle damage during active inflammation. Antisynthetase syndrome with ILD requires immunosuppression targeting the lung disease, with mycophenolate or rituximab often preferred.

The association between dermatomyositis and malignancy is well-established, with adult patients having a 3-8 fold increased risk of cancer compared to age-matched populations. Cancer may be diagnosed before, concurrent with, or after dermatomyositis diagnosis, with the highest risk in the three years surrounding myositis onset. The most common malignancies reflect age and sex-expected cancers, including ovarian cancer (elevated risk in women with dermatomyositis), lung cancer, gastrointestinal cancers, and breast cancer. Anti-TIF1-gamma antibodies particularly associate with malignancy, as do anti-NXP-2 antibodies. Age-appropriate cancer screening is recommended for all adult dermatomyositis patients, with many experts recommending more extensive evaluation including CT of chest, abdomen, and pelvis. Polymyositis carries lower malignancy risk than dermatomyositis.

Inclusion body myositis (IBM) warrants separate consideration given its distinct features and poor response to immunosuppression. IBM typically affects individuals over age 50, with characteristic patterns of asymmetric weakness involving finger flexors and quadriceps, causing difficulty gripping objects and frequent falls. Dysphagia is common. Unlike other inflammatory myopathies, CK elevation is modest (less than 10-12 times normal). Muscle biopsy shows inflammation combined with rimmed vacuoles and inclusion bodies. Critically, IBM responds poorly or not at all to immunosuppressive therapy, with treatment primarily supportive through physical therapy, dysphagia management, and fall prevention. The pathogenesis likely involves both inflammatory and degenerative components.

<image>Panel A: Treatment algorithm for inflammatory myopathy showing initial high-dose glucocorticoids, early addition of steroid-sparing agent (methotrexate, azathioprine, mycophenolate), and options for refractory disease (IVIG, rituximab), with expected response timeline. Panel B: Malignancy screening recommendations for adult dermatomyositis showing age-appropriate screening (colonoscopy, mammography, Pap smear), additional evaluation (CT chest/abdomen/pelvis, tumor markers), and high-risk features (anti-TIF1-gamma, older age, rapid onset). Panel C: Inclusion body myositis distinguishing features showing typical patient (male over 50), characteristic weakness pattern (finger flexors, quadriceps), biopsy findings (rimmed vacuoles, inclusions with inflammation), and poor immunosuppression response. Panel D: Antisynthetase syndrome triad diagram showing myositis, interstitial lung disease, and arthritis, with additional features (mechanic's hands, fever, Raynaud phenomenon) and anti-Jo-1 as the most common associated antibody.</image>

X. Mixed Connective Tissue Disease and Overlap Syndromes

Mixed connective tissue disease (MCTD) is a syndrome characterized by overlapping features of systemic lupus erythematosus, systemic sclerosis, and polymyositis, defined by the presence of high-titer anti-U1 RNP antibodies. The concept was introduced in the 1970s as a distinct entity with favorable prognosis, though this optimistic view has been tempered by recognition of serious complications. Features drawn from each component disease combine in varying patterns: SLE-like features include polyarthritis, serositis, and rash; scleroderma-like features include Raynaud phenomenon (nearly universal), sclerodactyly, and esophageal dysmotility; and polymyositis-like features include inflammatory myositis. The diagnosis requires high-titer anti-U1 RNP antibodies in the absence of other specific antibodies (anti-dsDNA, anti-Sm, anti-Scl-70).

Clinical manifestations of MCTD evolve over time, with some patients developing features that eventually permit reclassification as a specific connective tissue disease. Raynaud phenomenon is nearly universal and may be the presenting feature, often predating other manifestations by years. The pattern of Raynaud in MCTD is frequently severe with digital ischemia. Puffy, swollen hands ("sausage fingers") are characteristic early findings. Arthritis resembles rheumatoid arthritis with symmetric polyarticular involvement. Myositis when present resembles polymyositis. Pulmonary arterial hypertension represents a major cause of mortality and requires regular screening with echocardiography. Interstitial lung disease also occurs. Renal disease is generally less severe than in SLE. The prognosis, initially thought to be benign, is now recognized as variable depending on organ involvement.

Undifferentiated connective tissue disease (UCTD) describes patients with features suggesting systemic autoimmune disease but not meeting classification criteria for any specific diagnosis. These patients typically present with nonspecific symptoms such as Raynaud phenomenon, arthralgias, fatigue, and positive ANA without disease-specific autoantibodies. Some patients with UCTD eventually evolve to meet criteria for a defined connective tissue disease, while others remain undifferentiated long-term. Management is directed at specific symptoms rather than the underlying disease, with close monitoring for evolution.

Overlap syndromes occur when features of two or more distinct connective tissue diseases coexist in the same patient. Rhupus describes overlap of rheumatoid arthritis and SLE, with erosive arthritis and lupus features. Scleromyositis combines systemic sclerosis with inflammatory myositis. SLE and Sjogren syndrome commonly overlap, with anti-Ro/La antibodies occurring in both conditions. These overlap presentations may have autoantibody profiles reflecting each component disease. Management addresses the manifestations of each component disease, recognizing that treatment may need to be more intensive when multiple autoimmune processes are active.

<image>Panel A: Venn diagram illustration of mixed connective tissue disease showing overlapping features from SLE (arthritis, serositis, rash), systemic sclerosis (Raynaud, sclerodactyly, esophageal dysmotility), and polymyositis (inflammatory myopathy), with anti-U1 RNP antibodies at the center. Panel B: Clinical photographs of MCTD features including puffy swollen hands early in disease, Raynaud phenomenon with digital ischemia, sclerodactyly in later disease, and arthritis resembling rheumatoid pattern. Panel C: Evolution diagram showing how MCTD may remain stable, evolve to predominant SLE features, evolve to predominant scleroderma features, or evolve to predominant myositis, with timeline and frequency estimates. Panel D: Overlap syndrome examples showing rhupus (erosive arthritis with lupus features), scleromyositis (scleroderma with inflammatory myopathy), and SLE-Sjogren overlap, with distinguishing features and shared autoantibodies.</image>

Summary

• SLE is a prototypical systemic autoimmune disease characterized by autoantibodies, immune complex deposition, and multi-organ involvement; ANA is highly sensitive while anti-dsDNA and anti-Sm are specific
• Lupus nephritis occurs in approximately 50% of patients, with Class IV (diffuse proliferative) carrying the worst prognosis; treatment involves induction with mycophenolate or cyclophosphamide followed by maintenance therapy
• Systemic sclerosis is classified as limited (CREST features, PAH risk) versus diffuse (rapid skin progression, ILD and renal crisis risk), with autoantibody patterns predicting organ involvement
• Scleroderma renal crisis, presenting with hypertensive emergency and AKI, requires ACE inhibitor therapy; ILD and PAH are leading causes of mortality in systemic sclerosis
• Sjogren syndrome causes sicca symptoms from lymphocytic gland infiltration; anti-Ro and anti-La antibodies are characteristic; 5-10% lifetime lymphoma risk is the most serious complication
• Dermatomyositis features heliotrope rash and Gottron papules with proximal weakness; cancer screening is essential given 3-8 fold increased malignancy risk
• Antisynthetase syndrome includes myositis, ILD, arthritis, mechanic's hands, and anti-Jo-1 or related antibodies; ILD drives morbidity and mortality
• MCTD is defined by high-titer anti-U1 RNP antibodies with overlapping SLE, scleroderma, and myositis features; pulmonary hypertension is a major complication
• Treatment approaches are organ-based for systemic sclerosis and stratified by severity for SLE and inflammatory myopathies

Key Terms

This content is subject to the MIT License. © 2024–2026 Hibbert School of Medicine.

Read this lecture as Markdown